Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Dude51on Mar 07, 2021 11:48am
244 Views
Post# 32738648

RE:Spam all over stockhouse

RE:Spam all over stockhouseIf you going to spam about spam maybe change your handle to Fool instead of Joeking? Good name choice genius. Here is some news for your world:

• The gaseous delivery of NO only targets the lung, because it is instantaneously inactivated once it reaches the pulmonary circulation via its nitrosylation of iron in hemoglobin present in circulating erythrocytes. COVID-19 is a systemic infection, with involvement of the gut mucosa, renal tubules, heart, and CNS; hence inhaled NO cannot treat extrapulmonary disease. R-107 delivers R-100 systemically, reaching all organs where infection is active or preventing dissemination of active pulmonary infection to the periphery.

• Inhaled NO only reaches areas of lung with excellent ventilation. Since ARDS is associated with profound ventilation-perfusion mismatch, and many areas of the lung are poorly ventilated, inhaled gaseous delivery of NO misses delivery to the full lung. This is potentially a major limitation of NO gas delivery.


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse